COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Ireland Natalizumab (TYSABRI) Observational Program (iTOP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01943526
Recruitment Status : Completed
First Posted : September 17, 2013
Last Update Posted : May 4, 2018
Information provided by (Responsible Party):

Brief Summary:
The objectives of this study are to assess the long-term safety and impact on disease activity and progression of natalizumab (Tysabri) in participants with relapsing remitting multiple sclerosis (RRMS) in a clinical practice setting.

Condition or disease Intervention/treatment
Relapsing-Remitting Multiple Sclerosis Biological: natalizumab

Detailed Description:
iTOP is a retrospective and prospective Irish observational study of participants receiving natalizumab, with each participant to be followed for 3 years. This study is designed to address the long-term safety profile and the long-term impact on disease activity and progression of natalizumab with marketed use. Collection of efficacy and safety data at 6- monthly intervals to coincide with regular clinic visits and routine clinical practice will therefore be undertaken during the iTOP observational period.

Layout table for study information
Study Type : Observational
Actual Enrollment : 191 participants
Observational Model: Case-Only
Time Perspective: Other
Official Title: Ireland Natalizumab (TYSABRI®) Observational Program (iTOP)
Actual Study Start Date : November 30, 2011
Actual Primary Completion Date : December 31, 2017
Actual Study Completion Date : December 31, 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Natalizumab

Intervention Details:
  • Biological: natalizumab
    Natalizumab will not be provided as a part of this study. Participants will receive natalizumab as prescribed by their treating physician.
    Other Names:
    • Tysabri
    • BG00002

Primary Outcome Measures :
  1. Number of participants experiencing Serious Adverse Events (SAEs) [ Time Frame: up to 3 years ]

Secondary Outcome Measures :
  1. Disability progression as determined by Expanded Disability Status Scale (EDSS) [ Time Frame: Up to 3 years ]
    Disability progression is defined as at least a 1.0 point increase on the EDSS from Baseline that is sustained over 6 months. The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist.

  2. MS disease activity as determined by annualized relapse rate (ARR) [ Time Frame: Up to 3 years ]
    A clinical relapse is defined as new or recurrent neurological symptoms, not associated with fever, lasting for at least 24 hours, and followed by a period of 30 days of stability or improvement. New or recurrent neurological symptoms that occur less than 30 days following the onset of a protocol-defined relapse should be considered part of the same relapse.

  3. MS disease activity as determined by distribution of the total number of relapses during the study [ Time Frame: Up to 3 years ]
  4. MS disease activity as determined by time to first relapse [ Time Frame: Up to 3 years ]
  5. MS disease activity as determined by number of participants with relapse [ Time Frame: Up to 3 years ]
  6. MS disability progression and MS disease activity summarized for subpopulations according to baseline characteristics [ Time Frame: Up to 3 years ]
    Prognostic factors for disability progression and MS disease activity will be assessed in different participant cohorts stratified according to their baseline characteristics: Participant demographics including age, gender; Disease History, including diagnosis and duration at baseline; Baseline EDSS; Number of relapses within 1 and 2 years before baseline; MRI parameters at baseline; Prior use of disease modifying therapy, anti-neoplastic, immunosuppressant or immunomodulator therapy

  7. MS disease activity as determined by MRI parameters [ Time Frame: Up to 3 years ]
  8. Evaluation of short-term disease outcomes as assessed by EDSS progression [ Time Frame: Up to 1 year ]
  9. Evaluation of short-term disease outcomes as assessed by occurrence of relapses [ Time Frame: Up to 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with RRMS who are being treated with natalizumab and patients who meet the criteria defined in the indication statement for prescription in Ireland. Existing patients will be enrolled retrospectively.

Key Inclusion Criteria:

  • Must give written informed consent and assent, as applicable.
  • Decision to treat with natalizumab must precede enrollment.
  • Patient characteristics and contraindications to treatment with natalizumab in accordance with prescribing information.
  • Must be receiving natalizumab (Tysabri) for the treatment of RRMS in accordance with the natalizumab indication statement.
  • Must have a documented diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS).

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01943526

Layout table for location information
Research site
Cork, County Cork, Ireland
Research site
Dublin, County Dublin, Ireland
Research site
Galway, County Galway, Ireland
Research site
Tralee, County Kerry, Ireland
Research site
Sligo, County Sligo, Ireland
Sponsors and Collaborators
Layout table for investigator information
Study Director: Medical Director Biogen
Layout table for additonal information
Responsible Party: Biogen Identifier: NCT01943526    
Other Study ID Numbers: TYS-IRL-11-4
First Posted: September 17, 2013    Key Record Dates
Last Update Posted: May 4, 2018
Last Verified: April 2018
Keywords provided by Biogen:
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Immunologic Factors
Physiological Effects of Drugs